Table 4 Comparison of the predicted and experimentally tested effects of mutations on the aggregation propensity of amyloidogenic proteins.

Peptide Aβ42 A21G

-16

-

[84]

Peptide Aβ42 E22K

15

+

[84]

Peptide Aβ42 E22G

29

+

[84]

Peptide Aβ42 E22Q

5

+

[84]

Peptide Aβ42 F19P

-68

-

[85]

Peptide Aβ42 F19T

-63

-

[35]

Peptide Aβ42 D23N

16

+

[86]

Peptide Aβ42 F19D

-118

-

[12]

Peptide Aβ42 I31L

-15

-

[87]

Peptide Aβ42 I32L

-15

-

[87]

Peptide Aβ42 I41G

-62

-

[87]

Peptide Aβ42 I41A

-49

-

[87]

Peptide Aβ42 I41L

-12

-

[87]

Peptide Aβ42 A42G

-10

-

[87]

Peptide Aβ42 A42V

32

+

[87]

Peptide Aβ42 Δ 1–4

59

+

[88]

Peptide Aβ42 Δ 1–9

237

+

[88]

Peptide Aβ42 Δ 40–42

-63

-

[88]

Peptide AβgΔ 41–42

-34

-

[36]

Peptide Aβg5

89

+

[36]

Peptide Aβg6

111

+

[36]

Peptide Aβg7

167

+

[36]

Peptide Aβ42 V12E+V18E+M35T+I41N

-312

-

[87]

Peptide Aβ42 F19S+L34P

-123

-

[87]

TAU R5L

2

+

[89]

TAU R406W

2

+

[90]

TAU G272V

2

+

[90]

TAU Y310W

0

=

[39]

TAU P301L

1

+

[40]

TAU S320F

2

+

[91]

α-synucleinA30P

-1

=

[92]

α-synucleinE46K

2

+

[92]

α-synucleinA53T

-1

+

[92]

α-synucleinA76E

-5

-

[93]

α-synucleinA76R

-3

-

[93]

Amylin (Rat) R18H

9

+

[94]

Amylin (Rat) L23F

17

+

[94]

Amylin (Rat) V26I

11

+

[94]

Amylin (Rat) R18H+L23F+V26I

34

+

[94]

Amylin (human) (22–27) N22A

21

+

[68]

Amylin (human) (22–27) F23A

-59

-

[68]

Amylin (human) (22–27)G24A

16

+

[68]

Amylin (human) (22–27) I26A

-61

-

[68]

Amylin (human) (22–27) L27A

-23

-

[68]

Amylin (human) S20G

-106

+

[95]

Amylin (human) ProIAPP

-90

+?

[96]

Human PrP H111A

5

+/=

[97]

Human PrP H111K

0

-/=

[97]

Human PrP A117V

7

+

[97]

Human PrP V210I

1

+

[98]

Stefin R68X

37

+

[41]

Stefin G4R

-6

-

[41]

SH3 n47a

17

+

[46]